Company Overview of Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel proprietary therapies for the treatment of prostate cancer and other hormonally-driven diseases in the United States. Its lead drug candidate includes galeterone, an oral small molecule drug candidate, which is in Phase II clinical trials for the treatment of castration resistant prostate cancer. The company was founded in 2004 and is headquartered in Cambridge, Massachusetts.
Cambridge, MA 02142
Founded in 2004
Key Executives for Tokai Pharmaceuticals, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $422.0K
Compensation as of Fiscal Year 2013.
Tokai Pharmaceuticals, Inc. Key Developments
Tokai Pharmaceuticals, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 08:00 AM
Mar 2 15
Tokai Pharmaceuticals, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 08:00 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Jodie Pope Morrison, Chief Executive Officer, President and Director.
Tokai Pharmaceuticals Obtains Exclusive, Worldwide License from the Johns Hopkins University
Jan 21 15
Tokai Pharmaceuticals reported that it has entered into an agreement with the Johns Hopkins University related to the development of a companion diagnostic to determine the AR-V7 status of patients with castration-resistant prostate cancer (CRPC) for use with the Company's lead product, galeterone, which is in development for the treatment of AR-V7 positive metastatic CRPC. Under the agreement, the Company has obtained an exclusive, worldwide license from the Johns Hopkins University to patent applications and know-how covering an assay that has been used to determine the AR-V7 status of prostate cancer patients.
Tokai Pharmaceuticals, Inc. Appoints Stephen Buckley, Jr. to the Board of Directors and as Chair of the Audit Committee
Jan 9 15
Tokai Pharmaceuticals, Inc. announced that Stephen Buckley, Jr. has joined the company’s board of directors and will serve as chair of the audit committee. Mr. Buckley spent 25 years as a partner of Ernst & Young LLP, where he led assurance and advisory teams serving public and private companies in life sciences and other technologies. Mr. Buckley ran Ernst & Young’s Life Sciences Industry Practice of New England from 1991 to 2006, and was director of its New England Entrepreneurial Services Group from 1991 to 2001. He was previously a partner in the Boston, Massachusetts office of Arthur Young until its merger into Ernst & Young in 1989.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|